8 results about "Erythromycin resistance" patented technology

The invention provides a compound as shown in a formula (I), and a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, a metabolite, ester, pharmaceutically acceptable salt or prodrug thereof, or a pharmaceutical composition thereof, which have better antibacterial and anti-inflammatory effects, can be used as an antibiotic, and can be used for preparing a pharmaceutical preparation for preventing and treating diseases. The compound can treat infection caused by pathogenic microorganisms resistant to erythromycin and telithromycin, and simultaneously acts on double targets of ribosome and topoisomerase.

The application discloses a food-like lactobacillus double-plasmid multi-gene editing system based on CRISPR / Cas9 technology and application thereof. The food-like lactobacillus double-plasmid multi-gene editing system comprises (1) a plasmid pCRI01 comprising the following elements: a Cas9 protein coding gene; a temperature-sensitive replicon pSC101; an sgRNA expression module targeting the replicon of the plasmid pCRI02, which is controlled by an inducible promoter Pnis; an ampicillin resistance; and (2) a plasmid pCRI02 comprising the following elements: at least one sgRNA expression module driven by a P23 promoter; a lambda-Red recombinase system comprising Exo, Beta and Gam genes; an erythromycin resistance marker gene; and a kanamycin resistance gene. The multi-gene editing system provided by the application is a small-size pCRI01 and pCRI02 double-plasmid system, and the number of transformed cells after resistance screening is significantly improved; and the gene editing efficiency mediated by the pCRI plasmid is greatly improved with the assistance of the lambda-Red recombinase system.

This article provides a macrolide-quinolone compound of formula (I) which has good antibacterial and anti-inflammatory effects and can be used as an antibiotic, especially for the treatment of infections caused by erythromycin-resistant pathogens in clinical practice.

The invention belongs to the technical field of gene engineering, and particularly relates to application of a FloA gene as a target spot to reduction of drug resistance of methicillin-resistant staphylococcus aureus to erythromycin. The invention discovers that after the FloA gene of the methicillin-resistant staphylococcus aureus is knocked out by adopting a recombinant vector, the minimum inhibitory concentration of erythromycin to the methicillin-resistant staphylococcus aureus can be obviously reduced. Therefore, the FloA gene as a target spot can be used for screening drugs for reducing the drug resistance of the methicillin-resistant staphylococcus aureus to the erythromycin, and the FloA gene is combined with the erythromycin to realize better activity of resisting the methicillin-resistant staphylococcus aureus; meanwhile, by constructing the FloA gene knockout methicillin-resistant staphylococcus aureus strain, a foundation can be laid for researching the erythromycin drug resistance mechanism of the methicillin-resistant staphylococcus aureus.

The invention discloses a lactobacillus foodstuff-like double-plasmid multi-gene editing system based on a CRISPR / Cas9 technology and application of the lactobacillus foodstuff-like double-plasmid multi-gene editing system. The lactobacillus food-like double-plasmid multi-gene editing system comprises: (1) a plasmid pCRI01, wherein the plasmid pCRI01 comprises the following elements: a Cas9 protein coding gene; a temperature sensitive replicon pSC101; the sgRNA expression module is used for targeting a second plasmid replicon and is regulated and controlled by an inducible promoter Pnis; ampicillin resistance is achieved; (2) a plasmid pCRI02 comprising the following elements: at least one sgRNA expression module driven by a P23 promoter; the lambda-Red recombinase system comprises an Exo gene, a Beta gene and a Gam gene; an erythromycin resistance marker gene; and a kanamycin resistance gene. After the multi-gene editing system provided by the invention is a small-size pCRI01 and pCRI02 double-plasmid system, the number of transformants after resistance screening is remarkably increased, and under the assistance of a lambda-Red recombinase system, the pCRI plasmid mediated gene editing efficiency is greatly improved.

The application discloses erythromycin micellar type ointment for overcoming erythromycin multidrug resistance and a preparation method and application thereof, and the erythromycin micellar type ointment is composed of liposoluble acid modified dextran, erythromycin, hydrophilic gel matrix material and water; wherein the mass ratio of the liposoluble acid modified dextran and the erythromycin is 1:1-1:10. The application effectively solves the killing of erythromycin resistant bacteria by erythromycin, and can also effectively reduce the occurrence of the drug resistance phenomenon of non-drug resistant bacteria.

Provided are a compound represented by formula (I), a stereoisomer, tautomer, isotopic marker, nitrogen oxide, solvate, polymorph, metabolite, ester, pharmaceutically acceptable salt, or prodrug thereof, or a pharmaceutical composition. The compound has good antibacterial and anti-inflammatory effects, can be used as an antibiotic, can treat infections caused by pathogenic microorganisms resistant to erythromycin and telithromycin, and simultaneously acts on two targets, i.e., ribosomes and topoisomerase.

The invention discloses a construction method and application of engineering bacteria based on bacillus methylophilus. The method comprises the following steps: designing left and right homologous arms of Rel of an endogenous gene of bacillus methylophilus and a primer of an erythromycin resistance gene MslR in a plasmid pXY3, performing PCR amplification on a corresponding sequence, inserting fragments into XbaII and XhoII restriction enzyme cutting sites of the plasmid PXY3, transferring the constructed plasmid into escherichia coli E.coli T1, and culturing at 37 DEG C; then, preparing competent bacillus methylophilus, and introducing the plasmid subjected to methylation modification into the competent bacillus methylophilus through electrotransformation, so as to obtain recombinant bacillus methylophilus. According to the invention, an efficient gene knockout system of the strain is established, the technical blank of genome editing is filled, the regulation effect of the (p) ppGpp synthetase gene Rel on strain growth, methanol metabolism and organic acid synthesis is definite, an engineering strain and technical support for methanol biotransformation are provided, and a foundation is laid for breaking through the bottlenecks of slow strain growth and low substrate utilization efficiency.